OR WAIT null SECS
March 27, 2023
Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.
March 24, 2023
Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.
Harm Reduction Therapeutics and Catalent have signed a commercial supply agreement for naloxone nasal spray to reverse opioid overdoses.
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.
A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.
March 23, 2023
The recent document will guide the use of DHT-derived data in regulatory decision-making for drugs and biological products.
Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years.
March 22, 2023
Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.
In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.
The combined solutions are currently available on the market.